Examining the link between COVID-19 and psoriasis

Retrospective Clinical Study of COVID-19 Associated With the Condition and Treatment of Patients With Chinese Psoriasis

This study looks at how COVID-19 affects people with psoriasis and whether their skin condition or treatment changes after getting the virus.

Quick facts

• Study type: Observational
• Enrollment: 2500 (estimated)
• Sex: All
• Sponsor: Xijing Hospital (other)
• Locations: 12 sites (Chongqing, Chongqing and 11 other locations)
• Trial ID: NCT05961605 on ClinicalTrials.gov

What this trial studies

This observational study conducts a retrospective analysis to evaluate the correlation between COVID-19 infection and the condition of psoriasis patients. It utilizes data from psoriasis patient databases across multiple centers, where patients are followed up via telephone to gather information on the severity of COVID-19, changes in psoriasis condition, and adjustments in treatment methods. The study aims to provide insights into how COVID-19 may impact psoriasis patients and their treatment regimens.

Who should consider this trial

Good fit: Ideal candidates include psoriasis patients of any age who are registered in the psoriasis patient database and can provide follow-up information.

Not a fit: Patients with conditions that prevent them from participating in the follow-up process may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could enhance understanding of how COVID-19 affects psoriasis patients, potentially leading to improved management strategies.

How similar studies have performed: While there may be limited studies directly correlating COVID-19 with psoriasis, the approach of analyzing patient databases for retrospective insights has been utilized in other contexts with varying degrees of success.

Eligibility criteria

Inclusion criteria ----

1. No age limit, both male and female are accepted;
2. Psoriasis patients registered in the database;
3. Patients or their families can cooperate to complete the follow-up information survey (questionnaire, telephone, etc.) independently, and ensure the authenticity of the data provided.

Exclusion criteria ----

Patients are thought having conditions which are not appropriated for attending this clinical trial.

Where this trial is running

Chongqing, Chongqing and 11 other locations

• The First Affiliated Hospital of Chongqing Medical University — Chongqing, Chongqing, China (COMPLETED)
• The First Hospital of Lanzhou University — Lanzhou, Gansu, China (COMPLETED)
• Dermatology Hospital of Southern Medical University — Guangzhou, Guangdong, China (COMPLETED)
• The Second Hospital of Jilin University — Changchun, Jilin, China (COMPLETED)
• Dalian Dermatosis Hospital — Dalian, Liaoning, China (COMPLETED)
• Xining First People's Hospital — Xining, Qinghai, China (COMPLETED)
• Xijing Hospital, The Fourth Military Medical University — Xi'an, Shaanxi, China (RECRUITING)
• Shanghai Skin Disease Hospital, Tongji University School of Medicine — Shanghai, Shanghai, China (COMPLETED)
• The University of Hong Kong-Shenzhen Hospital — Shenzhen, Shenzhen, China (COMPLETED)
• West China Hospital, Sichuan University — Chengdu, Sichuan, China (COMPLETED)
• Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital — Tianjin, Tianjin, China (COMPLETED)
• People's Hospital of Xinjiang Uygur Autonomous Region，Xinjiang Key Laboratory of Dermatology Research — Ürümqi, Xinjiang, China (COMPLETED)

Study contacts

• Principal investigator: GANG WANG, M.D. — Xijing Hospital, The Fourth Military Medical University
• Study coordinator: GANG WANG, M.D.

Conditions: Psoriasis Patients, COVID-19, psoriasis, covid-19